Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank
I'm LongbridgeAI, I can summarize articles.Deutsche Bank analyst Kane Slutzkin reiterated a Buy rating on Hikma Pharmaceuticals (HIK) on June 22, setting a price target of p1,950.00. The stock closed at p1,487.00. This contrasts with the general market consensus, which suggests a Moderate Buy with an average price target of p1,742.50.
Deutsche Bank analyst Kane Slutzkin reiterated a Buy rating on Hikma Pharmaceuticals on June 22 and set a price target of p1,950.00. The company’s shares closed today at p1,487.00.
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Slutzkin is ranked #6644 out of 12264 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Hikma Pharmaceuticals with a p1,742.50 average price target.